Alnoor, M.D.

Dr. Alnoor is a faculty member in the Department of Pathology and Laboratory Medicine at the University of Miami Miller School of Medicine, with specialized expertise in hematopathology, molecular diagnostics, and anatomic and clinical pathology. He earned his MBBS from Jinnah Medical and Dental College, University of Karachi, and completed his internship in Medicine and Surgery at Aga Khan University Hospital in Karachi, Pakistan. He then pursued residency training in Anatomic and Clinical Pathology at the University of Tennessee Health Science Center/St. Jude Children’s Research Hospital, followed by fellowships in Hematopathology at the University of Utah Health/ARUP Laboratories and in Molecular Genetic Pathology at Washington University in St. Louis.
Dr. Alnoor has distinguished himself through significant contributions to diagnostic pathology, research, and medical education. His key accomplishments include authoring multiple peer-reviewed publications in hematopathology and molecular pathology—highlighted by first-author works in American Journal of Hematology and The Journal of Molecular Diagnostics—and leading clinical validation projects for next-generation sequencing and PCR-based assays in hematologic malignancies. He has received competitive honors such as the Association for Pathology Informatics Travel Award and the Association for Molecular Pathology Trainee Travel Award.
In addition to his research and diagnostic work, Dr. Alnoor is actively involved in education, regularly teaching residents, fellows, and laboratory staff. He has presented his work at national and international conferences and remains committed to advancing the field of precision diagnostics in hematopathology and molecular genetics.

Dr. Alnoor's research program is centered on developing translational molecular tools to advance cancer diagnostics and precision oncology, with a particular emphasis on hematologic malignancies.His early work investigated the genomics of VEXAS syndrome, a multisystem autoinflammatory disorder with a known predisposition to myeloid neoplasms. This experience has shaped his broader interest in characterizing the clinical and molecular complexity of pre-malignant and immune-driven disorders that evolve into hematologic cancers.

A key focus of his current work involves applying Oxford Nanopore long-read sequencing technology to study tumor-specific methylation patterns in circulating tumor DNA. These efforts aim to enable non-invasive cancer detection and distinguish clonal hematopoiesis from true neoplastic variants.During his molecular genetic pathology fellowship at Washington University in St. Louis, Dr. Alnoor has been engaged in several advanced clinical genomics initiatives. He validated Haplotect, a haplotype-based method for detecting DNA contamination and bone marrow chimerism in next-generation sequencing assays, enhancing assay reliability and clinical utility. He is currentlycompleting a study evaluating Illumina short-readsequencing for the detection of measurable residualdisease in acute myeloid leukemia, benchmarking itsperformance against flow cytometry.

His future work aims to integrate AI-driven classifiers using methylation and genomic features to enhance disease classification, prognostication,and real-time clinical decision-making. Through interdisciplinary collaboration, his research seeks to bridge molecular diagnostics, computational pathology, and clinical oncology to advance the field of precision medicine.